TSHA NASDAQ
Credit Risk of going bust: lower than 53% of companies Debt: 4.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99.5%), Taysha Gene Therapies, Inc. would be worth roughly what it owes.
Total debt $55.6M against a stock market value of $1.30B.
Distance to default 5.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $24.6M (short-term plus half of long-term), stock volatility 71.0%; Altman Z'' 3.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Dallas, TX 75247
US
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nagendran Sukumar | S-Sale | 200,000 | $6.24 | 2026-07-10 |
| Stalfort John A III | A-Award | 21,335 | — | 2026-06-01 |
| Stalfort John A III | A-Award | 42,671 | $5.97 | 2026-06-01 |
| Donenberg Phillip B. | A-Award | 21,335 | — | 2026-06-01 |
| Donenberg Phillip B. | A-Award | 42,671 | $5.97 | 2026-06-01 |